Answers are grounded in this paper and cite their sources.
Osteoporosis is a major health burden, with estrogen deficiency after menopause as its primary cause. Whether obesity, insulin resistance, and type 2 diabetes mellitus (T2DM) relate to bone mineral density (BMD) similarly before and after menopause remains unclear. Because “obesity” encompasses distinct exposures, we distinguished general, central/visceral, subcutaneous/fat distribution, and lean-mass phenotypes. We searched PubMed (2016–2026) for studies analyzing women with obesity, insulin resistance, or T2DM; assessing BMD, osteoporosis, or fracture risk; and including both pre- and postmenopausal women as subgroups or comparing results by menopausal status. From 1884 records obtained by the database search, 14 studies met the criteria, including approximately 2.55 million women, with pre- and postmenopausal women split almost equally. In premenopausal women, visceral adipose tissue, body fat percentage, elevated HOMA-IR, and central obesity were associated with low BMD. In postmenopausal women, lean mass loss (sarcopenia), subcutaneous adipose tissue dis-tribution, metabolic syndrome components, and adipokine dysregulation were among the factors associated with low BMD. Regional fat deports showed differing associations with BMD across menopause, although these findings derive largely from single studies or small subgroups. Metabolic disorder–BMD relationships are modified by menopausal status: visceral adiposity is consistently associated with lower premenopausal BMD, whereas sarcopenic obesity and adipokine imbalance are associated with postmenopausal bone loss. These findings require confirmation by longitudinal and interventional studies but provide a biologically plausible basis for menopausal-specific risk-assessment hypotheses.
No takes yet. Share an insight, caveat, or question.
Gursky et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: